|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For example, a recent study has shown that MTG16 can repress not only wild-type E2A-mediated transcription, but also leukemia fusion protein E2A-Pbx1-mediated transcription, suggesting that MTG16 may serve as a potential therapeutic target in acute lymphoblastic leukemia expressing the E2A-Pbx1 fusion protein.
|
29358956 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study thus suggests that RNF6 overexpression in leukemia is under the direction of PBX1 and that the PBX1/RNF6 axis can be developed as a novel therapeutic target of leukemia.
|
26971355 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite the induced expression of E2A-PBX1, no hematopoietic disease was observed, strongly suggesting that additional genetic alterations are required to develop leukemia.
|
27088431 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results show how the oncogenic fusion protein E2A-PBX1 perturbs signaling pathways upstream of PLCγ2 and renders leukemias amenable to targeted therapeutic inhibition.
|
27758892 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In preleukemic mice, conditional Pax5 deletion cooperated with E2A-PBX1 to expand progenitor B cell subpopulations, increasing penetrance and shortening leukemia latency.
|
26301816 |
2015 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The observed in vitro and in vivo anti-leukemic potency of the αCD19-AON immunoconjugate provides the first preclinical proof-of-principle that t(1;19)(+) high risk B-lineage ALL can be treated with leukemia-specific biotherapeutic agents that knock-down E2A-PBX1 expression.
|
22990208 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide molecular insights into E-protein-driven differentiation of B-cells and the mechanism of E-protein silencing, and reveal the PCET/KIX interaction as a therapeutic target for E2A-PBX1-induced leukemia.
|
22972988 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Namely, we have identified significant associations of overexpressed IGF2BP1 with ETV6/RUNX1-positive (r(2)=0.7891, y=0.8105x-0.4471, p<0.0001), underexpressed IGF2BP2 with E2A/PBX1-positive (p<0.01), and overexpressed IGF2BP2 and IGF2BP3 with MLL/AF4-positive (r(2)=0.6571, y=0.1507x-0.2722, p<0.0001, and r(2)=0.7022, y=0.6482x-0.7660, p<0.0001, respectively) leukemia.
|
21414819 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite improvements in current combinational chemotherapy regimens, the prognosis of the (1;19)(q23;p13) translocation (E2A/PBX1)-positive B-cell precursor acute lymphoblastic leukemia (ALL) is poor in pediatric leukemia patients.
|
19922767 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lessons from the analysis of children with TCF3-PBX1 ALL could help to identify treatment components essential for this leukemia subtype.
|
18024406 |
2007 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
|
17593026 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeted-E2A-PBX1 inhibition leads to reduced expression of the EB-1 and Wnt16b genes; aberrant expression of these genes may be a key step in leukemogenesis in t(1;19)-positive pre-B leukemia.
|
16769578 |
2006 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We demonstrated efficient downregulation induced by anti-E2A-PBX1 siRNA in 697 t(1;19)-positive leukemia cells.
|
16769578 |
2006 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the TS-2 acute lymphoblastic leukemia (ALL) cell line that contains a t(1;19)(q23;p13.3) but lacks E2A-PBX1 fusion typically present in leukemias with this translocation.
|
15744350 |
2005 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven distinct leukemia subtypes were identified representing known leukemia subtypes including: BCR-ABL, E2A-PBX1, TEL-AML1, rearrangements in the MLL gene, hyperdiploid karyotype (i.e., > 50 chromosomes), and T-ALL as well as a new leukemia subtype.
|
14633779 |
2003 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since the E2A, PBX1 and HLF proteins all appear to function as transcription factors, it appears likely that the oncogenic fusion proteins contribute to leukemia development by causing abnormal transcriptional regulation of key target genes.
|
12700034 |
2003 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prenatal origin of the leukemia was assessed in 15 pediatric patients by screening for the clonotypic E2A-PBX1 translocation in neonatal blood spots, or Guthrie cards, obtained from the children at the time of birth.
|
12415113 |
2002 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To illustrate the usefulness of this new technology the E2A-PBX1 fusion gene transcript expression level for several human leukaemia cell lines that are positive and negative for cytogenetically detectable t(1;19) was determined.
|
11843816 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia.
|
10500199 |
1999 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In human leukemias, a HOX gene (HOXA9) and two non-HOX homeobox genes (PBX1 and HOX11) are involved in chromosomal translocations.
|
9885434 |
1998 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fusion with E2A converts the Pbx1 homeodomain protein into a constitutive transcriptional activator in human leukemias carrying the t(1;19) translocation.
|
7910944 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fusion with E2A alters the transcriptional properties of the homeodomain protein PBX1 in t(1;19) leukemias.
|
8183558 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our observations suggest that there could be heterogeneity in the molecular events among adult leukemias carrying the t(1;19) and that the E2A/PBX1 fusion formation might also be associated with an adverse treatment outcome in adult leukemias as in childhood leukemias.
|
7894030 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia.
|
8327485 |
1993 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Leukemias that express hybrid oncoproteins such as E2A-Pbx1 or Bcr-Abl have had a poor prognosis in most studies.
|
1348433 |
1992 |